骨髓间充质干细胞来源细胞外囊泡输注治疗COVID-19相关呼吸衰竭:随机安慰剂对照剂量临床试验
这项美国5中心前瞻性2期双盲随机安慰剂对照剂量试验纳入102例COVID-19相关中重度ARDS患者,第1天和第4天分别输注安慰剂、10 mL ExoFlo或15 mL ExoFlo(15 mL ExoFlo与85 mL生理盐水混合)。主要终点60天全因死亡率在意向治疗人群中15 mL ExoFlo组较安慰剂组降低但未达统计学显著(χ2,P=.1343)。事后亚组分析中,15 mL ExoFlo组60天死亡率较安慰剂组降低(RR 0.385,95%CI 0.159-0.931,P=.0340,n=50);18~65岁中重度ARDS参与者RR 0.423(95%CI 0.173-1.032,P=.0588,n=24);18~65岁全部参与者无通气天数改善(P=.0455,n=50)。作者认为15 mL ExoFlo在重症或危重型COVID-19相关呼吸衰竭患者中安全。
要点
- 意向治疗人群60天死亡率:15 mL ExoFlo组较安慰剂组降低但未达统计学显著(χ2,P=.1343)。
- 事后亚组分析:15 mL ExoFlo组60天死亡率较安慰剂组降低(RR 0.385,95%CI 0.159-0.931,P=.0340,n=50)。
- 18~65岁中重度ARDS参与者:15 mL ExoFlo组60天死亡率RR 0.423(95%CI 0.173-1.032,P=.0588,n=24)。
- 18~65岁全部参与者无通气天数在15 mL ExoFlo组改善(P=.0455,n=50)。
- 未报告治疗相关不良事件;15 mL ExoFlo在重症或危重型COVID-19相关呼吸衰竭患者中安全。
适用人群与场景
- COVID-19相关中重度ARDS患者(N=102),来自美国5个中心。
- 事后亚组分析纳入18~65岁中重度ARDS参与者(n=24)及18~65岁全部参与者(n=50)。
处置流程与药物剂量
- 第1天和第4天输注安慰剂、10 mL ExoFlo或15 mL ExoFlo。
- 15 mL ExoFlo与85 mL生理盐水混合后输注(ExoFlo-15)。
研究设计与关键结果
- 研究设计:前瞻性2期多中心双盲随机安慰剂对照剂量试验,美国5个中心,N=102例COVID-19相关中重度ARDS患者,随机接受安慰剂、10 mL ExoFlo或15 mL ExoFlo(第1天和第4天输注)。
- 主要终点:意向治疗人群60天全因死亡率,15 mL ExoFlo组较安慰剂组降低但未达统计学显著(χ2,P=.1343)。
- 未报告治疗相关不良事件。
- 事后亚组分析:15 mL ExoFlo组60天死亡率较安慰剂组降低(RR 0.385,95%CI 0.159-0.931,P=.0340,n=50)。
- 事后亚组分析:18~65岁中重度ARDS参与者中,15 mL ExoFlo组60天死亡率RR 0.423(95%CI 0.173-1.032,P=.0588,n=24)。
- 事后亚组分析:18~65岁全部参与者中,15 mL ExoFlo组无通气天数改善(P=.0455,n=50)。
证据类型、等级与局限
- 证据类型:前瞻性2期多中心双盲随机安慰剂对照剂量临床试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为15 mL ExoFlo在重症或危重型COVID-19相关呼吸衰竭患者中安全。
- 作者认为在18~65岁参与者中,两次15 mL ExoFlo较安慰剂使60天死亡率风险降低较意向治疗人群全部年龄受试者进一步改善。
指南或共识出处
- ClinicalTrials.gov注册号NCT04493242。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Bone marrow mesenchymal stem cell (BM-MSC)-derived extracellular vesicles (ExoFlo) convey the immunomodulatory and regenerative properties of intact BM-MSCs. This study aimed to determine the safety and efficacy of ExoFlo as treatment for moderate to severe ARDS in patients with severe COVID-19.
RESEARCH QUESTION: Do two doses of ExoFlo safely reduce mortality in COVID-19-associated moderate to severe ARDS compared with placebo?
STUDY DESIGN AND METHODS: A prospective phase 2 multicenter double-anonymized randomized placebo-controlled dosing trial was conducted at five sites across the United States with infusions of placebo, 10 mL of ExoFlo, or 15 mL of ExoFlo on days 1 and 4. Patients (N = 102) with COVID-19-associated moderate to severe ARDS were enrolled and randomized to treatment. Adverse events were documented throughout the study. The primary outcome measure was all-cause 60-day mortality rate. Secondary outcomes included time to death (overall mortality); the incidence of treatment-emergent serious adverse events; proportion of discharged patients at 7, 30, and 60 days; time to hospital discharge; and ventilation-free days.
RESULTS: No treatment-related adverse events were reported. Mortality (60-day) in the intention-to-treat population was reduced with 15 mL ExoFlo mixed with 85 mL normal saline (ExoFlo-15) compared with placebo (not significant, χ2, P = .1343). For the post hoc subgroup analyses, 60-day mortality was decreased with ExoFlo-15 compared with placebo (relative risk, 0.385; 95% CI, 0.159-0.931; P = .0340; n = 50). With ExoFlo-15, a relative risk of 0.423 (95% CI, 0.173-1.032; P = .0588; n = 24) was determined for participants aged 18 to 65 years with moderate to severe ARDS. Ventilation-free days improved with ExoFlo-15 (P = .0455; n = 50) for all participants aged 18 to 65 years.
INTERPRETATION: The 15 mL dose of ExoFlo was found to be safe in patients with severe or critical COVID-19-associated respiratory failure. In participants aged 18 to 65 years, the risk reduction in 60-day mortality was further improved from subjects of all ages in the intention-to-treat population after two doses of 15 mL of ExoFlo compared with placebo.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT04493242; URL: www.
CLINICALTRIALS: gov.
参考来源
- Lightner AL, Sengupta V, Qian S, et al. Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19: A Randomized, Placebo-Controlled Dosing Clinical Trial. Chest. 2023. PMID: 37356708. doi:10.1016/j.chest.2023.06.024
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。